The presence of extended-spectrum β-lactamase as a risk factor for MDR in clinical isolation of Escherichia coli

被引:0
|
作者
Asgharzadeh Kangachar, Sh [1 ]
Mojtahedi, A. [2 ]
机构
[1] Guilan Univ Med Sci, Fac Paramed, Langroud, Iran
[2] Guilan Univ Med Sci, Mol & Cellular Res Ctr, Fac Med, Rasht, Iran
关键词
URINARY-TRACT-INFECTIONS; ANTIBIOTIC-RESISTANCE; ANTIMICROBIAL RESISTANCE; PATHOGENS; PREVALENCE; INTEGRONS; PATTERNS; BACTERIA; STRAINS; SUSCEPTIBILITY;
D O I
暂无
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Significant increases in antibiotic resistance have become a critical dilemma in healthcare systems around the world. Enterobacteriaceae acquired different mechanisms of antibiotic resistance such as ESBLs production and transposon attainment, which hold antibiotic resistance genes. This may create multidrug resistant (MDR) strains. Antibiotic resistance patterns vary in different geographical regions. The present estimated-cross sectional study is aimed to determine antibiotic resistance pattern of 182 E. coli strains to 20 antibiotics. Three different methods were applied to detect the ESBL-producing E. coli. Observations revealed that oxacillin, amoxicillin and ampicillin had the lowest effect, while imipenem, gentamicin and nitrofurantoin had the highest impact on clinical E. coli strains in our region. Three different methods, including double disk synergy test (DDST) (30 mm), double disk synergy test (DDST) (20mm) and combined disk test were used to identify ESBL-producing E. coli. The prevalence of ESBL producers was at a 35.71% rate. Findings of this study indicate that there is no significant difference between these three methods in identifying ESBLproducing E. coli. There was a significant relation between ESBL production and resistance to three other classes of antibiotics, including protein synthesis inhibitor, Quinolones and Metabolite analogues. Moreover, antibiotic resistance rate in ESBL-producing E. coli was significantly higher than non ESBL-producing isolates. The MDR was at a 65.93% rate. Unfortunately, the rate of antibiotic resistance is globally increasing; this is due to several factors such as inappropriate antibiotic use, incomplete course of antibiotics use, protracted length of stay in hospitals and self-medication. Resistance mechanisms such as ESBL production and MDR cause treatment failure. Our findings suggest that ESBL production is a risk factor for MDR in clinical E. coli. Therefore, Physicians are recommended to stop excessive and long term administration of antibiotics.
引用
收藏
页码:98 / 109
页数:12
相关论文
共 50 条
  • [41] Extended-spectrum -lactamase producing Escherichia coli isolated from wild birds in Saskatoon, Canada
    Parker, D.
    Sniatynski, M. K.
    Mandrusiak, D.
    Rubin, J. E.
    LETTERS IN APPLIED MICROBIOLOGY, 2016, 63 (01) : 11 - 15
  • [42] Wild Boars Carry Extended-Spectrum β-Lactamase- and AmpC-Producing Escherichia coli
    Holtmann, Anna R.
    Meemken, Diana
    Mueller, Anja
    Seinige, Diana
    Buettner, Kathrin
    Failing, Klaus
    Kehrenberg, Corinna
    MICROORGANISMS, 2021, 9 (02) : 1 - 13
  • [43] Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections
    Vachvanichsanong, P.
    McNeil, E. B.
    Dissaneewate, P.
    EPIDEMIOLOGY AND INFECTION, 2020, 149
  • [44] Phenotypic and Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Bangladesh
    Lina, Taslima T.
    Khajanchi, Bijay K.
    Azmi, Ishrat J.
    Islam, Mohammad Aminul
    Mahmood, Belal
    Akter, Mahmuda
    Banik, Atanu
    Alim, Rumana
    Navarro, Armando
    Perez, Gabriel
    Cravioto, Alejandro
    Talukder, Kaisar A.
    PLOS ONE, 2014, 9 (10):
  • [45] Fecal Colonization with Extended-Spectrum Beta-Lactamase and AmpC-Producing Escherichia coli
    Al-Agamy, Mohamed H.
    El Mahdy, Taghrid S.
    Shibl, Atef M.
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [46] Epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in Sweden 2007-2011
    Brolund, A.
    Edquist, P. J.
    Makitalo, B.
    Olsson-Liljequist, B.
    Soderblom, T.
    Wisell, K. Tegmark
    Giske, C. G.
    CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (06) : O344 - O352
  • [47] Phenotypic and genotypic characterizations of extended-spectrum beta-lactamase-producing Escherichia coli in Thailand
    Bubpamala, Jiranun
    Khuntayaporn, Piyatip
    Thirapanmethee, Krit
    Montakantikul, Preecha
    Santanirand, Pitak
    Chomnawang, Mullika T.
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 2151 - 2157
  • [48] Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli
    Al-Tamimi, Mohammad
    Abu-Raideh, Jumana
    Albalawi, Hadeel
    Shalabi, Marwan
    Saleh, Saiel
    MICROBIAL DRUG RESISTANCE, 2019, 25 (08) : 1132 - 1141
  • [49] Molecular Characteristics of Extended-Spectrum β-Lactamase-Producing Escherichia coli in a University Teaching Hospital
    Osawa, Kayo
    Shigemura, Katsumi
    Shimizu, Rika
    Kato, Ayaka
    Kusuki, Mari
    Jikimoto, Takumi
    Nakamura, Tatsuya
    Yoshida, Hiroyuki
    Arakawa, Soichi
    Fujisawa, Masato
    Shirakawa, Toshiro
    MICROBIAL DRUG RESISTANCE, 2015, 21 (02) : 130 - 139
  • [50] Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: Prevalence, β-lactamase distribution, phylogroups, and co-resistance
    Hansen, Dennis Schroder
    Schumacher, Helga
    Hansen, Frank
    Stegger, Marc
    Hertz, Frederik Boetius
    Schonning, Kristian
    Justesen, Ulrik Stenz
    Frimodt-Moller, Niels
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 44 (03) : 174 - 181